Potential of the bioflavonoids in the prevention/treatment of ocular disorders

Journal of Pharmacy and Pharmacology

Volumn 62, Issue 8, 2010, Pages 951-965

  Majumdar, Soumyajit ^a   Srirangam, Ramesh ^a  

^a UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

anti angiogenic; anti inflammatory; antioxidant; flavonoids; ocular drug delivery

Indexed keywords

3,6 DIHYDROXYFLAVONE; 3,7 DIHYDROXYFLAVONE; ANTHOCYANOSIDE; APIGENIN; AURANTIIN; BAICALEIN; BIOFLAVONOID; CATECHIN; CHELATING AGENT; CHRYSIN; CYANIDIN CHLORIDE; EPICATECHIN; EPICATECHIN GALLATE; EPIGALLOCATECHIN GALLATE; ERIODICTYOL; FISETIN; FLAVONE DERIVATIVE; FREE RADICAL; GALANGIN; GINKGO BILOBA EXTRACT; GLYCOSIDE; HESPERETIN; HESPERIDIN; KAEMPFEROL; LUTEOLIN; MYRICETIN; NARINGENIN; QUERCETIN; RUTOSIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; BLOOD EYE BARRIER; BLOOD RETINA BARRIER; CANCER INHIBITION; CATARACT; CELL DEATH; CELL PROTECTION; CHELATION; CLOSED ANGLE GLAUCOMA; CONCENTRATION RESPONSE; CONGENITAL GLAUCOMA; CORNEA DISEASE; CORNEA SCAR; DIABETES MELLITUS; DIABETIC RETINOPATHY; DRUG ACTIVITY; DRUG ADMINISTRATION ROUTE; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG POTENCY; DRUG TARGETING; DRY EYE; EVAPORATIVE DRY EYE; EYE BLOOD FLOW; EYE DISEASE; EYE PROTECTION; EYE TOXICITY; GLAUCOMA; HUMAN; HYPERGLYCEMIA; HYPOXIA; IN VIVO STUDY; INTRAOCULAR HYPERTENSION; LOCAL THERAPY; NEOPLASM; NONHUMAN; NORMAL TENSION GLAUCOMA; OPEN ANGLE GLAUCOMA; OPTIC NERVE DISEASE; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHYSICAL CHEMISTRY; PRIMARY GLAUCOMA; REFRACTION ERROR; RETINA GANGLION CELL; RETINA MACULA AGE RELATED DEGENERATION; RETINA PIGMENT EPITHELIOPATHY; REVIEW; SECONDARY GLAUCOMA; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION; SUBRETINAL NEOVASCULARIZATION; SYSTEMIC THERAPY; TEAR DEFICIENT DRY EYE; TRACHOMA; UVEITIS;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; CHEMISTRY, PHARMACEUTICAL; DRUG ADMINISTRATION ROUTES; DRUG CARRIERS; EYE DISEASES; FLAVONOIDS; HUMANS; TREATMENT OUTCOME;

EID: 77954932471     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp.62.08.0001     Document Type: Review

References (121)

1. Resnikoff S et al. Global data on visual impairment in the year 2002. Bull World Health Org 2004 82 : 844 851.
2. Ryskulova A et al. Self-reported age-related eye diseases and visual impairment in the United States: results of the 2002 national health interview survey. Am J Public Health 2008 98 : 454 461.
3. Foster A et al. Changing patterns in global blindness: 1988-2008. Community Eye Health 2008 21 : 37 39.
4. Davies KM, Schwinn KE. Flavonoids: Chemistry, Biochemistry and Applications. Boca Raton, CRC Press, 2006.
5. Ross JA, Kasum CM. Dietary flavonoids: bioavailability, metabolic effects, and safety. Annu Rev Nutr 2002 22 : 19 34.
6. Crozier A et al. Dietary phenolics: chemistry, bioavailability and effects on health. Nat Prod Rep 2009 26 : 1001 1043.
7. Ohia SE et al. Pharmacological consequences of oxidative stress in ocular tissues. Mutat Res 2005 579 : 22 36.
8. Erickson KK et al. Vascular permeability in ocular disease and the role of tight junctions. Angiogenesis 2007 10 : 103 117.
9. Kyselova Z et al. Pharmacological prevention of diabetic cataract. J Diabetes Complications 2004 18 : 129 140.
10. Head KA. Natural therapies for ocular disorders, part two: cataracts and glaucoma. Altern Med Rev 2001 6 : 141 166.
11. Wilkinson-Berka JL. Vasoactive factors and diabetic retino- pathy: vascular endothelial growth factor, cycoloxygenase-2 and nitric oxide. Curr Pharm Des 2004 10 : 3331 3348.
12. Singh R et al. Diabetic retinopathy: an update. Indian J Ophthalmol 2008 56 : 178 188.
13. Friedman DS et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004 122 : 564 572.
14. Beatty S et al. The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv Ophthalmol 2000 45 : 115 134.
15. Infeld DA, O'Shea JG. Glaucoma: diagnosis and management. Postgrad Med J 1998 74 : 709 715.
16. Coleman AL. Glaucoma. Lancet 1999 354 : 1803 1810.
17. Mozaffarieh M et al. Oxygen and blood flow: players in the pathogenesis of glaucoma. Mol Vis 2008 14 : 224 233.
18. Izzotti A et al. The role of oxidative stress in glaucoma. Mutat Res 2006 612 : 105 114.
19. Flammer J et al. The impact of ocular blood flow in glaucoma. Prog Retin Eye Res 2002 21 : 359 393.
20. The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf 2007 5 : 75 92.
21. Wakamatsu T et al. Tearful relations: oxidative stress, inflam- mation and eye diseases. Arquivos Brasileiros de Oftalmologia 2008 71 : 72 79.
22. Pietta PG. Flavonoids as antioxidants. J Nat Prod 2000 63 : 1035 1042.
23. Nijveldt RJ et al. Flavonoids: a review of probable mechanisms of action and potential applications. Am J Clin Nutr 2001 74 : 418 425.
24. Rice-Evans CA et al. Structure-antioxidant activity relationships of flavonoids and phenolic acids. Free Radic Biol Med 1996 20 : 933 956.
25. Chen YC et al. Wogonin, baicalin, and baicalein inhibition of inducible nitric oxide synthase and cyclooxygenase-2 gene expressions induced by nitric oxide synthase inhibitors and lipopolysaccharide. Biochem Pharmacol 2001 61 : 1417 1427.
26. Kim BH et al. Down-regulatory effect of quercitrin gallate on nuclear factor-kappa B-dependent inducible nitric oxide synthase expression in lipopolysaccharide-stimulated macrophages RAW 264.7. Biochem Pharmacol 2005 69 : 1577 1583.
27. Martinez-Florez S et al. Quercetin attenuates nuclear factor-kappaB activation and nitric oxide production in interleukin-1beta-activated rat hepatocytes. J Nutr 2005 135 : 1359 1365.
28. Sakata K et al. Inhibition of inducible isoforms of cyclooxy-genase and nitric oxide synthase by flavonoid hesperidin in mouse macrophage cell line. Cancer Lett 2003 199 : 139 145.
29. Pemp B, Schmetterer L. Ocular blood flow in diabetes and age-related macular degeneration. Can J Ophthalmol 2008 43 : 295 301.
30. Park YH, Chiou GC. Structure-activity relationship (SAR) between some natural flavonoids and ocular blood flow in the rabbit. J Ocul Pharmacol Ther 2004 20 : 35 42.
31. Xu XR et al. Effects of dihydrogenation of flavones and number of hydroxy groups in the molecules on ocular blood flow in rabbits and retinal function recovery in rats. J Ocul Pharmacol Ther 2004 20 : 311 320.
32. Liu SX et al. Increase of ocular blood flow by some phytogenic compounds. J Ocul Pharmacol Ther 1996 12 : 95 101.
33. Park YH et al. Structural requirements of flavonoids for increment of ocular blood flow in the rabbit and retinal function recovery in rat eyes. J Ocul Pharmacol Ther 2004 20 : 189 200.
34. Chiou GC, Xu XR. Effects of some natural flavonoids on retinal function recovery after ischemic insult in the rat. J Ocul Pharmacol Ther 2004 20 : 107 113.
35. Chung HS et al. Ginkgo biloba extract increases ocular blood flow velocity. J Ocul Pharmacol Ther 1999 15 : 233 240.
36. Wimpissinger B et al. Influence of Ginkgo biloba on ocular blood flow. Acta Ophthalmol Scand 2007 85 : 445 449.
37. Steigerwalt RD et al. Effects of Mirtogenol on ocular blood flow and intraocular hypertension in asymptomatic subjects. Mol Vis 2008 14 : 1288 1292.
38. Maher P, Hanneken A. Flavonoids protect retinal ganglion cells from oxidative stress-induced death. Invest Ophthalmol Vis Sci 2005 46 : 4796 4803.
39. Maher P, Hanneken A. Flavonoids protect retinal ganglion cells from ischemia in vitro. Exp Eye Res 2008 86 : 366 374.
40. Hanneken A et al. Flavonoids protect human retinal pigment epithelial cells from oxidative-stress-induced death. Invest Ophthalmol Vis Sci 2006 47 : 3164 3177.
41. Johnson J et al. The flavonoid, eriodictyol, induces long-term protection in ARPE-19 cells through its effects on Nrf2 activation and phase 2 gene expression. Invest Ophthalmol Vis Sci 2009 50 : 2398 2406.
42. Jung SH et al. The flavonoid baicalin counteracts ischemic and oxidative insults to retinal cells and lipid peroxidation to brain membranes. Neurochem Int 2008 53 : 325 337.
43. Zhang B et al. Orally administered epigallocatechin gallate attenuates retinal neuronal death in vivo and light-induced apoptosis in vitro. Brain Res 2008 1198 : 141 152.
44. Zhang B et al. Epigallocatechin gallate, an active ingredient from green tea, attenuates damaging influences to the retina caused by ischemia/ reperfusion. Brain Res 2007 1159 : 40 53.
45. Hirooka K et al. The Ginkgo biloba extract (EGb 761) provides a neuroprotective effect on retinal ganglion cells in a rat model of chronic glaucoma. Curr Eye Res 2004 28 : 153 157.
46. Mojzis J et al. Antiangiogenic effects of flavonoids and chalcones. Pharmacol Res 2008 57 : 259 265.
47. Stoclet JC et al. Vascular protection by dietary polyphenols. Eur J Pharmacol 2004 500 : 299 313.
48. Paysant J et al. Different flavonoids present in the micronized purified flavonoid fraction (Daflon 500 mg) contribute to its anti-hyperpermeability effect in the hamster cheek pouch microcirculation. Int Angiol 2008 27 : 81 85.
49. Choi IY et al. Hesperidin inhibits expression of hypoxia inducible factor-1 alpha and inflammatory cytokine production from mast cells. Mol Cell Biochem 2007 305 : 153 161.
50. Zou Y, Chiou GC. Apigenin inhibits laser-induced choroidal neovascularization and regulates endothelial cell function. J Ocul Pharmacol Ther 2006 22 : 425 430.
51. Kim JH et al. Inhibition of choroidal neovascularization by homoisoflavanone, a new angiogenesis inhibitor. Mol Vis 2008 14 : 556 561.
52. Chen Y et al. Quercetin inhibits choroidal and retinal angiogenesis in vitro. Graefes Arch Clin Exp Ophthalmol 2008 246 : 373 378.
53. Tan WF et al. Quercetin, a dietary-derived flavonoid, possesses antiangiogenic potential. Eur J Pharmacol 2003 459 : 255 262.
54. Jackson SJ, Venema RC. Quercetin inhibits eNOS, microtubule polymerization, and mitotic progression in bovine aortic endothelial cells. J Nutr 2006 136 : 1178 1184.
55. Igura K et al. Resveratrol and quercetin inhibit angiogenesis in vitro. Cancer Lett 2001 171 : 11 16.
56. Donnini S et al. Divergent effects of quercetin conjugates on angiogenesis. Br J Nutr 2006 95 : 1016 1023.
57. Zhang Q et al. Green tea extract and (-)-epigallocatechin-3-gallate inhibit hypoxia- and serum-induced HIF-1alpha protein accumulation and VEGF expression in human cervical carcinoma and hepatoma cells. Mol Cancer Ther 2006 5 : 1227 1238.
58. Shirakami Y et al. (-)-Epigallocatechin gallate suppresses the growth of human hepatocellular carcinoma cells by inhibiting activation of the vascular endothelial growth factor-vascular endothelial growth factor receptor axis. Cancer Sci 2009 100 : 1957 1962.
59. Jung YD et al. EGCG, a major component of green tea, inhibits tumour growth by inhibiting VEGF induction in human colon carcinoma cells. Br J Cancer 2001 84 : 844 850.
60. Kim JD et al. Chemical structure of flavonols in relation to modulation of angiogenesis and immune-endothelial cell adhesion. J Nutr Biochem 2006 17 : 165 176.
61. Sung B et al. Fisetin, an inhibitor of cyclin-dependent kinase 6, down-regulates nuclear factor-kappaB-regulated cell proliferation, antiapoptotic and metastatic gene products through the suppression of TAK-1 and receptor-interacting protein-regulated IkappaBalpha kinase activation. Mol Pharmacol 2007 71 : 1703 1714.
62. Joussen AM et al. Treatment of corneal neovascularization with dietary isoflavonoids and flavonoids. Exp Eye Res 2000 71 : 483 487.
63. Bagli E et al. Luteolin inhibits vascular endothelial growth factor-induced angiogenesis; inhibition of endothelial cell survival and proliferation by targeting phosphatidylinositol 3'-kinase activity. Cancer Res 2004 64 : 7936 7946.
64. Fu B et al. Chrysin inhibits expression of hypoxia-inducible factor1alpha through reducing hypoxia-inducible factor- 1alpha stability and inhibiting its protein synthesis. Mol Cancer Ther 2007 6 : 220 226.
65. Lin CM et al. Chrysin inhibits lipopolysaccharide-induced angiogenesis via down-regulation of VEGF/VEGFR-2(KDR) and IL-6/IL-6R pathways. Planta Med 2006 72 : 708 714.
66. Tunon MJ et al. Potential of flavonoids as anti-inflammatory agents: modulation of pro-inflammatory gene expression and signal transduction pathways. Curr Drug Metab 2009 10 : 256 271.
67. Wakabayashi I. Inhibitory effects of baicalein and wogonin on lipopolysaccharide-induced nitric oxide production in macrophages. Pharmacol Toxicol 1999 84 : 288 291.
68. Yang LP et al. Baicalein reduces inflammatory process in a rodent model of diabetic retinopathy. Invest Ophthalmol Vis Sci 2009 50 : 2319 2327.
69. Nakamura N et al. Effects of baicalin, baicalein, and wogonin on interleukin-6 and interleukin-8 expression, and nuclear factor-kappab binding activities induced by interleukin-1beta in human retinal pigment epithelial cell line. Exp Eye Res 2003 77 : 195 202.
70. Shiratori K et al. The effects of naringin and naringenin on endotoxin-induced uveitis in rats. J Ocul Pharmacol Ther 2005 21 : 298 304.
71. Kawanishi K et al. Aldose reductase inhibitors from the nature. Curr Med Chem 2003 10 : 1353 1374.
72. Sreeraj M et al. Ophthalmic Drug Delivery Systems 2. New York: Marcel Dekker, Inc., 2003.
73. Maurice D, Mishima S. Ocular pharmacokinetics In : Sears ML, ed. Handbook of Experimental Pharmacology: Pharmacology of the Eye. Berlin: Springer, 1986: 19116.
74. Schoenwald RD, Ward RL. Relationship between steroid permeability across excised rabbit cornea and octanol-water partition coefficients. J Pharm Sci 1978 67 : 786 788.
75. Rothwell JA et al. Experimental determination of octanol-water partition coefficients of quercetin and related flavonoids. J Agric Food Chem 2005 53 : 4355 4360.
76. Bohm B. Introduction to Flavonoids. New York: Taylor & Francis, 1998.
77. Wu C et al. Preparation and evaluation of a Carbopol/HPMC- based in situ gelling ophthalmic system for puerarin. Yakugaku Zasshi 2007 127 : 183 191.
78. Qi H et al. Development of a poloxamer analogs/carbopol-based in situ gelling and mucoadhesive ophthalmic delivery system for puerarin. Int J Pharm 2007 337 : 178 187.
79. Zhang L et al. Ocular pharmacokinetics and availability of topically applied baicalein in rabbits. Curr Eye Res 2009 34 : 257 263.
80. Matsumoto H et al. Comparative assessment of distribution of blackcurrant anthocyanins in rabbit and rat ocular tissues. Exp Eye Res 2006 83 : 348 356.
81. Manach C et al. Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. Am J Clin Nutr 2005 81 : 230S 242S.
82. Manach C, Donovan JL. Pharmacokinetics and metabolism of dietary flavonoids in humans. Free Radic Res 2004 38 : 771 785.
83. Prasain JK, Barnes S. Metabolism and bioavailability of flavonoids in chemoprevention: current analytical strategies and future prospectus. Mol Pharm 2007 4 : 846 864.
84. Majumdar S, Srirangam R. Solubility, stability, physicochem-ical characteristics and in vitro ocular tissue permeability of hesperidin: a natural bioflavonoid. Pharm Res 2009 26 : 1217 1225.
85. Hirata A et al. Kinetics of radical-scavenging activity of hesperetin and hesperidin and their inhibitory activity on COX-2 expression. Anticancer Res 2005 25 : 3367 3374.
86. Mutoh M et al. Suppression of cyclooxygenase-2 promoter-dependent transcriptional activity in colon cancer cells by chemopreventive agents with a resorcin-type structure. Carci- nogenesis 2000 21 : 959 963.
87. Raso GM et al. Inhibition of inducible nitric oxide synthase and cyclooxygenase-2 expression by flavonoids in macrophage J774A.1. Life Sci 2001 68 : 921 931.
88. Crespo I et al. A comparison of the effects of kaempferol and quercetin on cytokine-induced pro-inflammatory status of cultured human endothelial cells. Br J Nutr 2008 100 : 968 976.
89. Nizamutdinova IT et al. Hesperidin, hesperidin methyl chalone and phellopterin from Poncirus trifoliata (Rutaceae) differentially regulate the expression of adhesion molecules in tumor necrosis factor-alpha-stimulated human umbilical vein endothelial cells. Int Immunopharmacol 2008 8 : 670 678.
90. Park HH et al. Flavonoids inhibit histamine release and expression of proinflammatory cytokines in mast cells. Arch Pharm Res 2008 31 : 1303 1311.
91. Jang YP et al. Anthocyanins protect against A2E photo-oxidation and membrane permeabilization in retinal pigment epithelial cells. Photochem Photobiol 2005 81 : 529 536.
92. Siu AW et al. Glutamate-induced retinal lipid and protein damage: the protective effects of catechin. Neurosci Lett 2008 432 : 193 197.
93. Heo J et al. Protective effects of epigallocatechin gallate after UV irradiation of cultured human lens epithelial cells. Korean J Ophthalmol 2008 22 : 183 186.
94. Costa BL et al. Orally administered epigallocatechin gallate attenuates light-induced photoreceptor damage. Brain Res Bull 2008 76 : 412 423.
95. Peng PH et al. Epigallocatechin-3-gallate reduces retinal ischemia/reperfusion injury by attenuating neuronal nitric oxide synthase expression and activity. Exp Eye Res 2008 86 : 637 646.
96. Yang SW et al. Protective effects of epigallocatechin gallate after UV irradiation in cultured human retinal pigment epithelial cells. Korean J Ophthalmol 2007 21 : 232 237.
97. Zhang B, Osborne NN. Oxidative-induced retinal degeneration is attenuated by epigallocatechin gallate. Brain Res 2006 1124 : 176 187.
98. Hodges LC et al. Intraocular pressure-lowering activity of phenolic antioxidants in normotensive rabbits. Curr Eye Res 1999 19 : 234 240.
99. Kim JH et al. Deguelin inhibits retinal neovascularization by down-regulation of HIF-1alpha in oxygen-induced retinopathy. J Cell Mol Med 2008 12 : 2407 2415.
100. Kim JH et al. Antiangiogenic effect of deguelin on choroidal neovascularization. J Pharmacol Exp Ther 2008 324 : 643 647.
101. Areias FM et al. Antioxidant effect of flavonoids after ascorbate/Fe(2+)-induced oxidative stress in cultured retinal cells. Biochem Pharmacol 2001 62 : 111 118.
102. Kim SY et al. The protection of the retina from ischemic injury by the free radical scavenger EGb 761 and zinc in the cat retina. Ophthalmologica 1998 212 : 268 274.
103. Kim YS et al. Genistein inhibits aldose reductase activity and high glucose-induced TGF-beta2 expression in human lens epithelial cells. Eur J Pharmacol 2008 594 : 18 25.
104. Huang R et al. Effect of the isoflavone genistein against galactose-induced cataracts in rats. Exp Biol Med (Maywood) 2007 232 : 118 125.
105. Li H et al. Inhibitive effect of genistein on interleukin-8 expression in cultured human retinal pigment epithelial cells. Methods Find Exp Clin Pharmacol 2006 28 : 295 299.
106. Pan JS et al. Inhibitive effect of genistein on hypoxia-induced basic fibroblast growth factor expression in human retinal pigment epithelium cells. J Ocul Pharmacol Ther 2006 22 : 103 109.
107. Wang B et al. Genistein inhibited hypoxia-inducible factor1alpha expression induced by hypoxia and cobalt chloride in human retinal pigment epithelium cells. Methods Find Exp Clin Pharmacol 2005 27 : 179 184.
108. Wang B et al. Genistein suppressed upregulation of vascular endothelial growth factor expression by cobalt chloride and hypoxia in rabbit retinal pigment epithelium cells. J Ocul Pharmacol Ther 2003 19 : 457 464.
109. Nakajima M et al. Normalization of retinal vascular permeability in experimental diabetes with genistein. Invest Ophthalmol Vis Sci 2001 42 : 2110 2114.
110. Yoon HS et al. Genistein produces reduction in growth and induces apoptosis of rat RPE-J cells. Curr Eye Res 2000 20 : 215 224.
111. Hayashi A et al. Genistein, a protein tyrosine kinase inhibitor, ameliorates retinal degeneration after ischemia-reperfusion injury in rat. Invest Ophthalmol Vis Sci 1997 38 : 1193 1202.
112. Kim JH et al. Homoisoflavanone inhibits retinal neovascularization through cell cycle arrest with decrease of cdc2 expression. Biochem Biophys Res Commun 2007 362 : 848 852.
113. Laabich A et al. Protective effects of myricetin and related flavonols against A2E and light mediated-cell death in bovine retinal primary cell culture. Exp Eye Res 2007 85 : 154 165.
114. Teng Y et al. Protective effect of puerarin on diabetic retinopathy in rats. Mol Biol Rep 2009 36 : 1129 1133.
115. Xuan B et al. Improvement of ocular blood flow and retinal functions with puerarin analogs. J Ocul Pharmacol Ther 1999 15 : 207 216.
116. Kook D et al. The protective effect of quercetin against oxidative stress in the human RPE in vitro. Invest Ophthalmol Vis Sci 2008 49 : 1712 1720.
117. Jiang Q et al. Quercetin attenuates UV- and H(2)O(2)-induced decrease of collagen type I in cultured human lens epithelial cells. J Ocul Pharmacol Ther 2008 24 : 164 174.
118. Cao XG et al. Responses of human lens epithelial cells to quercetin and DMSO. Invest Ophthalmol Vis Sci 2007 48 : 3714 3718.
119. Cornish KM et al. Quercetin metabolism in the lens: role in inhibition of hydrogen peroxide induced cataract. Free Radic Biol Med 2002 33 : 63 70.
120. Sanderson J et al. Quercetin inhibits hydrogen peroxide-induced oxidation of the rat lens. Free Radic Biol Med 1999 26 : 639 645.
121. Matsuda H et al. Structural requirements of flavonoids and related compounds for aldose reductase inhibitory activity. Chem Pharm Bull (Tokyo) 2002 50 : 788 795.